Wordt geladen...
REGN-EB3: First Approval
REGN-EB3 (INMAZEB(®), Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies—atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) —that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in th...
Bewaard in:
| Gepubliceerd in: | Drugs |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer International Publishing
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7799152/ https://ncbi.nlm.nih.gov/pubmed/33432551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01452-3 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|